PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-35.03%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-35.03%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-37.55%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-34.88%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-34.88%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
2.03%
Share count expansion well above RVPH's 2.75%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
2.03%
Diluted share count expanding well above RVPH's 2.75%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
9.51%
OCF growth under 50% of RVPH's 33.13%. Michael Burry might suspect questionable revenue recognition or rising costs.
9.65%
FCF growth under 50% of RVPH's 33.13%. Michael Burry would suspect weaker operating efficiencies or heavier capex burdens.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
63.42%
OCF/share CAGR of 63.42% while RVPH is zero. Bruce Berkowitz might see a slight advantage that could compound over time.
54.54%
OCF/share CAGR of 54.54% while RVPH is zero. Bruce Berkowitz would see if modest momentum can translate into a bigger competitive lead.
-31.27%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
85.15%
Positive 10Y CAGR while RVPH is negative. John Neff might see a substantial advantage in bottom-line trajectory.
56.20%
Positive 5Y CAGR while RVPH is negative. John Neff might view this as a strong mid-term relative advantage.
-42.46%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
-24.53%
Negative equity/share CAGR over 10 years while RVPH stands at 0.00%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
-57.00%
Negative 5Y equity/share growth while RVPH is at 0.00%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-54.63%
Negative 3Y equity/share growth while RVPH is at 0.00%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-2.92%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-9.07%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-5.00%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
41.18%
R&D growth drastically higher vs. RVPH's 71.75%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
22.12%
SG&A declining or stable vs. RVPH's 105.21%. David Dodd sees better overhead efficiency if it doesn't hamper revenue.